Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,

preformed on days 1-14 and day 28. complete CBC.

performed on days 1,2,7,14 and 28.

performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ

performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.

performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.

performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.

performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.

performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.

performed on day 28. score: 0-3 ; a higher score indicates better recovery.

performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.

performed on days 1-14 and day 28. a full examination by a doctor.

"performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain).~The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below.~For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)"

performed on days 1,14 and 28.

performed on days 1 and 28.

performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)